<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642561</url>
  </required_header>
  <id_info>
    <org_study_id>LC-RFA vs.TACE</org_study_id>
    <nct_id>NCT03642561</nct_id>
  </id_info>
  <brief_title>Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE</brief_title>
  <official_title>Liver Cancer Institiute ,Fudan University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With
      TACE
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conduct this clinical trial to evaluate the treatment outcome of RFA in HCC
      patients with tumor smaller than 7cm and tumor number less than five ,in comparison with TACE
      treatment.The primary outcome is overall survival.The secondary outcome is objective response
      rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>group 1 RFA alone group 2 TACE alone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>RFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in RFA group will accept RFA treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in TACE group will accept TACE treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>radiotherapy ablation</intervention_name>
    <description>We using Cool Tip system or RITA system to perform RFA</description>
    <arm_group_label>RFA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transarterial chemoembolization(TACE)</intervention_name>
    <description>TACE treatment is a first line treatment for BCLC stage B HCC</description>
    <arm_group_label>TACE group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  age 18 to 75 years ;

          -  HCC confirmed by pathological or clinical diagnosis according to the American
             Association for the Study of Liver Diseases criteria ;

          -  solitary HCC less than 7cm in diameter or multiple HCC lesions less 5

          -  the absence of portal/hepatic vein invasion, lymph node involvement and extrahepatic
             metastases;

          -  lesions visible on ultrasound with a safe path between the lesion and skin;

          -  an Eastern Cooperative Oncology Group performance status of 0-1;

          -  Child-Pugh class A or B cirrhosis.

        The exclusion criteria :

          -  received any other previous treatment for HCC;

          -  severe coagulation disorders;

          -  evidence of hepatic decompensation including hepatic encephalopathy, ascites as well
             as esophageal or gastric variceal bleeding;

          -  presence of serious medical comorbidities, including serious dysfunction of the heart
             or kidney ;

          -  currently had other malignancies in addition to HCC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenggang Ren, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Yin, doctor</last_name>
    <phone>+86-21-64041990</phone>
    <email>yin.xin@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Yin, doctor</last_name>
      <email>yin.xin@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>zhenggang Ren, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>July 25, 2020</last_update_submitted>
  <last_update_submitted_qc>July 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zheng-Gang Ren</investigator_full_name>
    <investigator_title>zhongshan hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make IPDavailable to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

